Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 4 Jun 2020 |
| Grant of Restricted Stock Units and Warrants to Employees in Genmab | 3 Jun 2020 |
| U.S. FDA Extends Review of sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosis | 2 Jun 2020 |
| Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis | 28 May 2020 |
| Genmab Announces Data to be Presented at the EHA25 Virtual Congress | 14 May 2020 |
| Genmab A/S has published its Articles of Association | 13 May 2020 |